Research news

Last week it was announced that the dementia drug, donanemab, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). This means it will be available under private prescription in the UK. However, it has been rejected by National Institute of Health and Care Excellence (NICE), so it will not be available on […]

News of the approval of the new Alzheimer’s drug has hit the headlines this week. Lecanemab has been approved by the MHRA, the UK’s regulator, but has been rejected by NICE so it will not be available on the NHS. Lecanemab is part of a new class of drugs that is emerging. It slows the […]

With social media platforms offering an easy way of finding out what is happening locally, it is easy to see the appeal for people living with dementia.  In order for these platforms to be even more effective, new research supported by Join Dementia Research highlights the need for social media guidance specifically for carers of […]

People with Down’s syndrome have an increased risk of developing Alzheimer’s disease. This is because most people with Down’s syndrome will have clumps of amyloid and tau proteins in their brains by the age of 40 – these are believed to cause Alzheimer’s disease. Two thirds of people with Down’s syndrome develop Alzheimer’s by the […]

Dementia Action Week took place from between 15 to 21 May this year and focused on getting an earlier diagnosis. Throughout the week, Join Dementia Research celebrated patients, members of the public, healthcare professionals and researchers involved in research. Here’s some of our highlights from this year’s campaign – a selection of videos and written […]

A clinical trial has revealed a new Alzheimer’s drug can successfully slow down decline in memory and thinking by 35 per cent. Donanemab has been shown to significantly reduce cognitive decline in people with early-stage Alzheimer’s disease. The trial by US pharmaceutical company Eli Lilly showed it has been successful in removing sticky amyloid plaques […]

The Government has announced two leaders in dementia research will co-chair a national mission dedicated to tackling the condition. Hilary Evans and Nadeem Sarwar have been appointed to the Dame Barbara Windsor Dementia Mission, following an announcement by George Freeman, the Minister for Science, Research and Innovation at the World Dementia Council Summit this week. […]

The findings of a research study that discovered a treatment for early stage Alzheimer’s disease have been hailed as “momentous” by Alzheimer’s Research UK.  The new treatment, lecanemab, is the first drug to slow cognitive decline in people with early signs of the condition. The CLARITY-AD study enrolled 1,795 patients with early-stage Alzheimer’s globally, including Join […]

A Scottish study which recruited participants through Join Dementia Research has published their findings on the effects of the adapted dementia diagnosis and consultation processes during the COVID-19 pandemic. The research has been co-produced by the University of Edinburgh and the Better Understanding Dementia Diagnosis (BUDDs) lived experience group, and funded by UK Research and […]

News that a potential treatment for early stage Alzheimer’s disease can slow cognitive decline is a significant development in dementia research. About the drug Lecanemab is an antibody that is designed to remove toxic beta-amyloid deposits; proteins that build up in the brains of people with Alzheimer’s disease. Following phase 3 clinical trials, pharmaceutical companies […]